In the world of neuromuscular disease, patience is not so much a virtue as an occupational requirement. Conditions such as myasthenia gravis and Charcot-Marie-Tooth disease can be chronic and progressive, and the physicians who study them must be willing to watch, wait, and document with the devotion of a naturalist tracking a rare bird through dense brush. Few clinicians have spent more time caring for and studying patients with these conditions than the woman who now steers late-phase neuroscience trials at Johnson & Johnson.
Dr. Sindhu Ramchandren is the company’s Executive Medical Director of Neuroscience, a title that undersells the amount of ground she has covered to earn it. She is a neurologist by training and a neuromuscular disorders specialist by devotion, and she describes her own motivation plainly. “I am passionate about developing therapies for rare neurologic diseases,” she says.
That sentence, plain as it sounds, is really the thesis of an entire career, and it has taken her from a Detroit neuromuscular clinic to the executive ranks of one of the world’s largest pharmaceutical companies.
The Making of a Neurologist
Dr. Ramchandren’s path began in medicine but bent quickly toward the rarest corners of it. She trained as a neurologist with a subspecialty in neuromuscular disorders, then added a Master of Science in clinical research design and statistical analysis, a combination that reads almost like a deliberate blueprint for the career that followed. It is one thing to diagnose a rare disease. It is another to know, with statistical precision, how to prove that a new therapy actually works against it.
That second skill would prove to be her signature.
Two Decades in the Clinic
Long before she ever set foot in a pharmaceutical boardroom, Dr. Ramchandren spent nearly a decade in academic medicine, building programs from the ground up. From June 2008 to March 2013, four years and ten months, she served as Assistant Professor of Neurology at Wayne State University in Detroit, where she was Co-Director of the Neuromuscular Program, Director of the MDA and CMT Clinic, and Associate Program Director of the Clinical Neurophysiology Fellowship.
During that stretch, she also secured an NIH K23 grant to develop and validate a pediatric quality of life instrument for Charcot-Marie-Tooth disease, a tool meant to measure something notoriously hard to measure: how a chronic, progressive nerve disorder actually affects a child’s daily life.
In April 2013, she moved to the University of Michigan Health System, where she remained until February 2018, four years and eleven months. There she became Director of the Muscular Dystrophy Association Care Center Program and Director of the Charcot-Marie-Tooth Center of Excellence Clinic, continued the K23-funded work on the pediatric CMT instrument, sat on the Institute for Healthcare Policy and Innovation, and served as a site principal investigator on neuromuscular clinical trials. It was, in effect, a decade spent building the exact clinical and academic foundation that would later let her move fluidly into industry.
From Academia to Industry
That move came in March 2018, when Dr. Ramchandren joined PRA Health Sciences as Medical Director for Neurology, a post she held for two years and eleven months, until January 2021, working out of the Raleigh-Durham-Chapel Hill area. It was her first sustained step outside the university walls, and it gave her exposure to clinical drug development across protocol design and regulatory processes.
She carried that exposure directly into her next chapter.
The Johnson & Johnson Years
In January 2021, Dr. Ramchandren joined Johnson & Johnson as Director of Clinical Development in Neuroscience and Global Clinical Leader for late-phase trials, a role she held for three years and five months. In June 2024, she was promoted to Executive Medical Director of Neuroscience, the position she still holds today, now two years and two months in, bringing her total tenure at the company to approximately five years and seven months.
It is in this role that her academic training in rare neuromuscular disease and her statistical fluency in trial design have converged most visibly. Public regulatory records and Johnson & Johnson materials connect her to the development of nipocalimab, including late-stage clinical development and regulatory work surrounding the therapy that became IMAAVY, the therapy that stands as one of the clearer public markers of what a career built on patience and precision can eventually produce.
She leads cross-functional matrix teams, oversees vendors and trial operations spanning medical, safety, and data quality monitoring, and is responsible for the scientific insight behind study designs, disease area strategy, protocol development, Investigator’s Brochures, annual regulatory reporting, and clinical study reports. It is, in short, the entire architecture of a late-stage drug program, resting on one person’s shoulders alongside her team.
A Specialist’s Specialist
What sets Dr. Ramchandren apart, even among her similarly credentialed peers, is the sheer range of rare disease territory she has worked across. Her subject matter expertise spans genetic and autoimmune neuromuscular disorders: pediatric and adult Duchenne muscular dystrophy, spinal muscular atrophy, muscular dystrophy more broadly, ALS, Charcot-Marie-Tooth disease, myasthenia gravis, myositis, chronic inflammatory demyelinating polyneuropathy, and MGUS neuropathy, along with paraneoplastic neuromuscular disorders. She also carries clinical experience in multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, epilepsy, and stroke, a breadth that few Executive Medical Directors in neuroscience can claim in equal measure.
It is worth pausing on that list, because rare disease work does not reward generalists. Each of those conditions demands its own literature, its own diagnostic criteria, its own community of patients who have often waited years for an accurate diagnosis, let alone a treatment. To have led clinics and clinical trial programs across that entire spectrum, and to have done so as both an academic clinician and, later, an industry strategist, is a rare professional arc in itself.
What Comes Next
At a moment when the neuroscience pipeline across the pharmaceutical industry is more crowded, and more scrutinized, than it has been in years, Dr. Ramchandren’s dual fluency, clinical and regulatory, academic and commercial, positions her as exactly the kind of leader the field now requires. She has spent her career translating the slow, patient work of the clinic into the disciplined, evidence-driven language of a field label. Few leaders in neuroscience drug development can say they have done both, and done both well.
“I am passionate about developing therapies for rare neurologic diseases.”
It is a simple line. But for a physician who has spent nearly two decades pursuing that mission, one sentence is really all that needs to be said.
